FDA Clearance Tracker · P030016-S035
EVO/EVO+VISIAN Implantable Collamer Lens
Last checked: Nov 20, 2026Latest source record: Mar 25, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Mar 25, 2022
Approved
Time to decision
1,240 days
Received Nov 1, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P030016-S035
- Device name
- EVO/EVO+VISIAN Implantable Collamer Lens
- Applicant
- STAAR Surgical Company
- Applicant location
- Monrovia, CA
- Received
- Nov 1, 2018
- Decided
- Mar 25, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P030016
Device type
- Device type
- Lens, intraocular, phakic (MTA)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the EVO/EVO+ Visian Implantable Collamer Lens. The ICL is indicated for use in patients 21-45 years of age:1. for the correction of myopia with spherical equivalent ranging from -3.0D to less than or equal to-15.0D with less than or equal to 2.5D of astigmatism at the spectacle plane;2. for the reduction of myopia with spherical equivalent ranging from greater than -15.0D to -20.0D with less than or equal to 2.5D of astigmatism at the spectacle plane;3. with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive history (within 0.5D for 1 year prior to implantation); and4.The ICL is intended for placement in the posterior chamber (ciliary sulcus) of the phakic eye.The EVO TICL is indicated for use in patients 21-45 years of age:1. for the correction of myopic astigmatism with spherical equivalent ranging from -3.0D to less than or equal to -15.0D (in the spectacle plane) with cylinder (spectacle plane) of 1.0D to 4.0D;2. for the reduction of myopic astigmatism with spherical equivalent ranging from greater than -15.0D to -20.0D (in the spectacle plane) with cylinder (spectacle plane)1.0D to 4.0D;3. with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive history (within 0.5 D for both spherical equivalent and cylinder for 1 year prior to implantation); and4. The TICL is intended for placement in the posterior chamber (ciliary sulcus) of the phakic eye.
Source documents
Other decisions for STAAR Surgical Company
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Visian Toric ICL (IMPLANTABLE COLLAMER LENS)PMA supplement
P030016-S001 · Decided Sep 13, 2018 · 4,521 days after receipt · Panel Track
Device type: Phakic toric intraocular lens (QCB) · Ophthalmology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.